Background:
Myeloid neoplasms are heterogeneous disorders characterized by chromosome abnormalities and somatic mutations in many genes that contribute to the pathogenesis and progression of the disease. This targeted, next generation sequencing test provides information on commonly mutated genes that have been identified as important prognostic and predictive markers, as well as targets for therapy. This test replaces the Myeloid-10 gene (AML10) panel test.
Methodology and reporting:
Next generation sequencing is performed on DNA extracted from whole blood or bone marrow. This test is a targeted assay covering 75 genes https://archerdx.com/myeloid-variantplex/ with variable full exon, full gene, or partial region coverage (depending on the specific locus). This assay will not detect genetic abnormalities outside the targeted regions. This test detects base substitutions, small insertions and deletions, copy number variations and internal tandem duplications/structural variations. This test does not detect large-scale changes.
An interpretive report will be provided.
Effective date: June 10, 2020
Specimen requirement and testing information:
Specimen: One (1) 4 mL whole blood or bone marrow in EDTA (lavender) tube
Test methodology: Next Generation Sequencing
Test code: MYEL75
Turnaround time (TAT):
STAT: N/A
Routine: 10 - 14 days
Set Up Days: Once a week
Stability:
Refrigerated: up to 5 days from collection date (for blood and bone marrow)
Frozen: up to 5 days from collection date (for blood and bone marrow)
Rejection criteria: Gross hemolysis or large blood clots.
Gene target list: https://archerdx.com/myeloid-variantplex
Sincerely,
Jeff Chan, MD, PhD
Director, Diagnostic Molecular Pathology Laboratory
Edwin S. Monuki, MD, PhD
Chair, Department of Pathology & Laboratory Medicine |
